Literature DB >> 10934535

Recombinant vaccinia viruses. Design, generation, and isolation.

C C Broder1, P L Earl.   

Abstract

The technologies of recombinant gene expression have greatly enhanced the structural and functional analyses of genetic elements and proteins. Vaccinia virus, a large double-stranded DNA virus and the prototypic and best characterized member of the poxvirus family, has been an instrumental tool among these technologies and the recombinant vaccinia virus system has been widely employed to express genes from eukaryotic, prokaryotic, and viral origins. Vaccinia virus is also the prototype live viral vaccine and serves as the basis for well established viral vectors which have been successfully evaluated as human and animal vaccines for infectious diseases and as anticancer vaccines in a variety of animal model systems. Vaccinia virus technology has also been instrumental in a number of unique applications, from the discovery of new viral receptors to the synthesis and assembly of other viruses in culture. Here we provide a simple and detailed outline of the processes involved in the generation of a typical recombinant vaccinia virus, along with an up to date review of relevant literature.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10934535     DOI: 10.1385/MB:13:3:223

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  85 in total

1.  Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.

Authors:  A P Durbin; C J Cho; W R Elkins; L S Wyatt; B Moss; B R Murphy
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

Review 2.  Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I.

Authors:  G Franchini; J Benson; R Gallo; E Paoletti; J Tartaglia
Journal:  AIDS Res Hum Retroviruses       Date:  1996-03-20       Impact factor: 2.205

3.  Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs.

Authors:  A Bridgen; R M Elliott
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

4.  An infectious clone of human parainfluenza virus type 3.

Authors:  M A Hoffman; A K Banerjee
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  A dominant selectable marker for the construction of recombinant poxviruses.

Authors:  D B Boyle; B E Coupar
Journal:  Gene       Date:  1988-05-15       Impact factor: 3.688

6.  Construction of chimeric vaccinia viruses by molecular cloning and packaging.

Authors:  F Scheiflinger; F Dorner; F G Falkner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

7.  Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection.

Authors:  I A Ramshaw; M E Andrew; S M Phillips; D B Boyle; B E Coupar
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

Review 8.  Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development.

Authors:  B Moss
Journal:  Dev Biol Stand       Date:  1994

9.  A PCR-based method for manipulation of the vaccinia virus genome that eliminates the need for cloning.

Authors:  P C Turner; R W Moyer
Journal:  Biotechniques       Date:  1992-11       Impact factor: 1.993

10.  Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection.

Authors:  H Shida; T Tochikura; T Sato; T Konno; K Hirayoshi; M Seki; Y Ito; M Hatanaka; Y Hinuma; M Sugimoto
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  9 in total

1.  Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors.

Authors:  Qingwen Jin; Jon Marsh; Kenneth Cornetta; Ghalib Alkhatib
Journal:  J Gen Virol       Date:  2008-10       Impact factor: 3.891

2.  Role for the conserved N-terminal cysteines in the anti-chemokine activities by the chemokine-like protein MC148R1 encoded by Molluscum contagiosum virus.

Authors:  Qingwen Jin; Jeffrey D Altenburg; Mohammad M Hossain; Ghalib Alkhatib
Journal:  Virology       Date:  2011-07-28       Impact factor: 3.616

3.  Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins.

Authors:  Katharine N Bossart; Lin-Fa Wang; Michael N Flora; Kaw Bing Chua; Sai Kit Lam; Bryan T Eaton; Christopher C Broder
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Authors:  Gerald V Quinnan; Xiao-Fang Yu; Mark G Lewis; Peng Fei Zhang; Gerd Sutter; Peter Silvera; Ming Dong; Anil Choudhary; Phuong T N Sarkis; Peter Bouma; Zhiqiang Zhang; David C Montefiori; Thomas C Vancott; Christopher C Broder
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates.

Authors:  D J Chabot; H Chen; D S Dimitrov; C C Broder
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells.

Authors:  Lokesh Agrawal; Xihua Lu; Jin Qingwen; Zainab VanHorn-Ali; Ioan Vlad Nicolescu; David H McDermott; Philip M Murphy; Ghalib Alkhatib
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  Targeted strategies for henipavirus therapeutics.

Authors:  Katharine N Bossart; John Bingham; Deborah Middleton
Journal:  Open Virol J       Date:  2007-09-28

8.  Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery.

Authors:  Yee-Peng Chan; Lianying Yan; Yan-Ru Feng; Christopher C Broder
Journal:  Methods Mol Biol       Date:  2009

9.  A rapid Orthopoxvirus purification protocol suitable for high-containment laboratories.

Authors:  Laura Hughes; Kimberly Wilkins; Cynthia S Goldsmith; Scott Smith; Paul Hudson; Nishi Patel; Kevin Karem; Inger Damon; Yu Li; Victoria A Olson; P S Satheshkumar
Journal:  J Virol Methods       Date:  2017-01-26       Impact factor: 2.623

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.